During a Community Case Forum series, breast cancer experts discussed the importance of testing for ESR1 mutations, in ...

The Food and Drug Administration approved ribociclib plus an aromatase inhibitor for hormone receptor (HR)–positive, ...

Breastfeeding is feasible for patients with hormone receptor–positive breast cancer who are undergoing a break of endocrine ...

While none of the experimental combinations met efficacy targets, durvalumab with monalizumab and ceralasertib showed ...

Amivantamab plus chemotherapy delivered promising OS trends compared with chemotherapy in EGFR-mutant advanced non-small cell ...

For patients with early breast cancer, hypofractionated radiation was noninferior to normofractionated radiation regarding ...

Patients with early-stage triple-negative breast cancer tended to have improved survival with neoadjuvant pembrolizumab plus ...

Belzutifan improved progression-free survival and objective response rate compared to everolimus in previously treated ...

Pembrolizumab plus chemoradiotherapy improved survival in patients with previously untreated, high-risk locally advanced ...

A group of oncology advanced practice providers discussed the use of BCMA-targeted bispecific antibodies for patients with ...

Study findings support tivozanib monotherapy for second-line treatment of certain patients with metastatic RCC, an expert ...

Experts discuss the adverse events observed with talquetamab, including oral toxicities and skin and nail issues, and how these are managed.